Vogt Frederick G 4

4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Dec 3, 2025

Form 4

Period: 2025-12-01

DirectorInterim CEO & General Counsel

Transactions

Exercise/Conversion
Common Stock
2025-12-01+41,669→ 476,232 total
Tax Payment
Common Stock
2025-12-01$2.23/sh−17,701$39,473→ 458,531 total
Exercise/Conversion
Common Stock
2025-12-02+10,417→ 468,948 total
Tax Payment
Common Stock
2025-12-02$2.14/sh−4,426$9,472→ 464,522 total
Exercise/Conversion
Restricted Stock Units
2025-12-01−41,669→ 208,344 total
→ Common stock (41,669 underlying)
Exercise/Conversion
Restricted Stock Units
2025-12-02−10,417→ 10,418 total
→ Common stock (10,417 underlying)

Footnotes (7)

[F1]Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
[F2]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
[F3]Represents common stock remaining after deducting the common stock withheld for taxes.
[F4]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
[F5]The remaining RSUs will vest in equal quarterly installments.
[F6]Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
[F7]Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.

Documents

1 file